Skip to content

Nelfinavir

Protease Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: nelfinavir mesilate, nelfinavir mesylate, viracept

OfpFDA approvedATC J05AE04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Nelfinavir is an ofp drug in the Protease Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Cytochrome P450 3A Inhibitors and HIV Protease Inhibitors. DrugCentral lists 27 molecular targets, including pol, protease and HIV-1 protease. Recorded indications include Human immunodeficiency virus infection.

  • Approval status: ofp (first approved 1997 by the FDA).
  • Drug class: Protease Inhibitor.
  • Mechanism of action: Cytochrome P450 3A Inhibitors; HIV Protease Inhibitors.
  • Molecular targets: pol, protease, HIV-1 protease and HIV-1 protease (27 listed in DrugCentral).
  • Indications: Human immunodeficiency virus infection.
  • ATC code: J05AE04 (Protease inhibitors).
  • Molecular formula: C32H45N3O4S; molecular weight 567.79 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Human immunodeficiency virus infection

Contraindications (8)

  • Breastfeeding (mother)
  • Depressive disorder
  • Diabetes mellitus
  • Diarrhea
  • Disease of liver
  • Hemophilia
  • Hyperglycemia
  • Pregnancy, function

Mechanism & targets

Mechanism of action (MoA)Cytochrome P450 3A Inhibitors; HIV Protease Inhibitors
Established pharmacologic classProtease Inhibitor

Molecular targets (27)

TargetGeneActionActivity
Pol polyproteinpolinhibitorKi 11.00
ProteaseproteaseunknownKi 10.15
ProteaseHIV-1 proteaseunknownKi 8.68
ProteaseHIV-1 proteaseunknownKi 8.49
Cytochrome P450 3A4CYP3A4unknownIC50 5.70
Progesterone receptorPGRunknownKi 5.24
Mu-type opioid receptorOPRM1unknownKi 5.23
D(1A) dopamine receptorDRD1unknownKi 5.19
Tyrosine-protein kinase FynFYNunknownIC50 5.10
Adenosine receptor A3ADORA3unknownKi 5.08
Sodium-dependent noradrenaline transporterSLC6A2unknownKi 5.06
Substance-K receptorTACR2unknownKi 5.01
Sodium-dependent dopamine transporterSLC6A3unknownKi 4.91
ATP-binding cassette sub-family G member 2ABCG2unknownIC50 4.90
Arachidonate 15-lipoxygenaseALOX15unknownIC50 4.86
Kappa-type opioid receptorOPRK1unknownKi 4.84
Mitogen-activated protein kinase 14MAPK14unknownIC50 4.74
Multidrug resistance protein 1ABCB1unknownIC50 4.70
Thromboxane-A synthaseTBXAS1unknownIC50 4.68
Mitogen-activated protein kinase 3MAPK3unknownIC50 4.65

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1997-03-14FDA—AGOURON

ATC classification

ATC codeTherapeutic hierarchy
J05AE04ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Protease inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: CYP3A4
  • FDA label: CYP2C19, CYP3A4, CYP3A5

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Lipodystrophy acquired718.4
Exposure during pregnancy717.8
Foetal exposure during pregnancy576.5
Virologic failure553.1
Viral mutation identified517.6
Mitochondrial toxicity517.0
Progressive external ophthalmoplegia471.3
Pathogen resistance390.5
Eyelid ptosis373.2
Drug resistance345.7
Premature baby232.8
Caesarean section226.1

Chemical structure

Molecular formulaC32H45N3O4S
Molecular weight567.79 g/mol
CAS number159989-64-7
InChIKeyQAGYKUNXZHXKMR-HKWSIXNMSA-N
PubChem CID64143
CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC1=CC=CC=C1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nelfinavir used for?

DrugCentral lists the following indications for Nelfinavir: Human immunodeficiency virus infection.

How does Nelfinavir work?

Nelfinavir is classified as Cytochrome P450 3A Inhibitors and HIV Protease Inhibitors; its molecular targets in DrugCentral include pol (inhibitor), protease, HIV-1 protease and HIV-1 protease.

When was Nelfinavir first approved?

Nelfinavir was first approved by the FDA in 1997.

What drug class does Nelfinavir belong to?

Nelfinavir is in the Protease Inhibitor class.

What is the chemical formula of Nelfinavir?

Nelfinavir has the molecular formula C32H45N3O4S and a molecular weight of 567.79 g/mol.

Browse: all drugs starting with N · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1997-03-14
AgencyFDA
Targets27
Indications1
FormulaC32H45N3O4S
DrugCentral ID1893
Interactive profile